EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A

Alok Srivastava, Aby Abraham, Fouzia Aboobacker, Gurbind Singh, Tulasi Geevar, Uday Kulkarni iD, Sushil Selvarajan, Anu Korula, Rutvi Gautam Dave, Mohana Shankar, Abraham S Singh, Anbu Jeba und 11 weitere

New England Journal of Medicine · 30.01.2025 · 392 (5) · 450-457

DOI: 10.1056/nejmoa2410597 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 30.01.2025. Verfasst von Alok Srivastava und 22 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Hematology, Christian Medical College Vellore, Ranipet Campus, Vellore, India (A.S., A.A., F.A., U.K., S.S., A.K., A.S.S., A.J…. Hauptthemen laut MEDLINE: Factor VIII, Genetic Therapy, Hematopoietic Stem Cell Transplantation, Hemophilia A. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Hemophilia of Georgia, NHLBI NIH HHS, Department of Biotechnology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIGenetic TherapyHematopoietic Stem Cell TransplantationHemophilia AHemorrhageAdultHumansMaleYoung AdultAntigens, CD34Follow-Up StudiesGenetic VectorsHematopoietic Stem CellsLentivirusTransduction, GeneticTransgenesTransplantation, AutologousTreatment Outcome

Substanzen

Antigens, CD34Factor VIII

Autor:innen und Institutionen

  • From the Department of Hematology, Christian Medical College Vellore, Ranipet Campus, Vellore, India (A.S., A.A., F.A., U.K., S.S., A.K., A.S.S., A.J., N.K., C.B., K.M.L., R.V.S.); Center for Stem Cell Research Unit of…

ORCID-Profile: Uday Kulkarni

Förderung

  • Hemophilia of Georgia
  • NHLBI NIH HHS
  • Department of Biotechnology, Ministry of Science and Technology, India
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Srivastava, A., Abraham, A., Aboobacker, F., Singh, G., Geevar, T., Kulkarni, U., Selvarajan, S., Korula, A., Dave, R. G., Shankar, M., Singh, A. S., Jeba, A., Kumaar, N., Benjamin, C., Lakshmi, K. M., Srivastava, V. M., Shaji, R. V., Nair, S. C., Brown, H. C., …, & Spencer, T. (2025). Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A. New England Journal of Medicine, 392(5), 450-457. https://doi.org/10.1056/nejmoa2410597

Vancouver

Srivastava A, Abraham A, Aboobacker F, Singh G, Geevar T, Kulkarni U, et al. Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A. New England Journal of Medicine. 2025;392(5):450-457. doi:10.1056/nejmoa2410597

BibTeX
@article{Srivastava2025,
  author = {Srivastava, Alok and Abraham, Aby and Aboobacker, Fouzia and Singh, Gurbind and Geevar, Tulasi and Kulkarni, Uday and Selvarajan, Sushil and Korula, Anu and Dave, Rutvi Gautam and Shankar, Mohana and Singh, Abraham S and Jeba, Anbu and Kumaar, Navien and Benjamin, Christopher and Lakshmi, Kavitha M and Srivastava, Vivi Miriam and Shaji, Ramachandran V and Nair, Sukesh C and Brown, Harrison C and Denning, Gabriela and Lollar, Pete and Doering, Christopher B and Spencer, Trent},
  title = {Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {5},
  pages = {450--457},
  doi = {10.1056/nejmoa2410597}
}
Kostenlos starten →